Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter?

References

• Jemal A , Bray F , Center MM , Ferlay J , Ward E , Forman D . Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• DeSantis CE , Lin CC , Mariotto AB , Siegel RL , Kramer JL , et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.
   PubMed Web of Science ®Google Scholar
• Hutchins LF , Unger JM , Crowley JJ , Coltman CA Jr , Albain KS . Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061–7.
   PubMed Web of Science ®Google Scholar
• Yancik R , Ganz PA , Varricchio CG , Conley B . Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol. 2001;19(4):1147–51.
   PubMed Web of Science ®Google Scholar
• Sclafani F , Cunningham D . Bevacizumab in elderly patients with metastatic colorectal cancer. J Geriatr Oncol. 2014;5(1):78–88.
   PubMed Web of Science ®Google Scholar
• Folprecht G , Seymour MT , Saltz L , Douillard JY , Hecker H , Stephens RJ , et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol. 2008;26(9):1443–51.
   PubMed Web of Science ®Google Scholar
• Goldberg RM , Tabah-Fisch I , Bleiberg H , de Gramont A , Tournigand C , Andre T , et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24(25):4085–91.
   PubMed Web of Science ®Google Scholar
• Folprecht G , Cunningham D , Ross P , Glimelius B , Di Costanzo F , Wils J , et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15(9):1330–8.
   PubMed Web of Science ®Google Scholar
• Joulain F , Proskorovsky I , Allegra C , Tabernero J , Hoyle M , Iqbal SU , et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer. 2013;109(7):1735–43.
   PubMed Web of Science ®Google Scholar
• Giantonio BJ , Catalano PJ , Meropol NJ , O'Dwyer PJ , Mitchell EP , Alberts SR , et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI , Fehrenbacher L , Hainsworth JD , Heim W , Berlin J , Holmgren E , et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23(15):3502–8.
   PubMed Web of Science ®Google Scholar
• Tol J , Koopman M , Cats A , Rodenburg CJ , Creemers GJ , Schrama JG , et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563–72.
   PubMed Web of Science ®Google Scholar
• Jonker DJ , O'Callaghan CJ , Karapetis CS , Zalcberg JR , Tu D , Au HJ , et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040–8.
   PubMed Web of Science ®Google Scholar
• Hecht JR , Mitchell E , Chidiac T , Scroggin C , Hagenstad C , Spigel D , et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27(5):672–80.
   PubMed Web of Science ®Google Scholar
• Moher DLA , Tetzlaff J , Altman DG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Moher D , Pham B , Jones A , Cook DJ , Jadad AR , Moher M , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–13.
   PubMed Web of Science ®Google Scholar
• Zintzaras E , Ioannidis JP . Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–37.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP . Bias in meta-analysis detected by a simple, graphical test. Experts' views are still needed. BMJ. 1998;316(7129)(469-70):70–1.
   Google Scholar
• Tabernero J , Van Cutsem E , Lakomy R , Prausova J , Ruff P , van Hazel GA , et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50(2):320–31.
   PubMed Web of Science ®Google Scholar
• Tabernero J , Garcia-Carbonero R , Cassidy J , Sobrero A , Van Cutsem E , Kohne CH , et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res. 2013;19(9):2541–50.
   PubMed Web of Science ®Google Scholar
• Siu LL , Shapiro JD , Jonker DJ , Karapetis CS , Zalcberg JR , Simes J , et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol. 2013;31(19):2477–84.
   PubMed Web of Science ®Google Scholar
• Grothey A , Van Cutsem E , Sobrero A , Siena S , Falcone A , Ychou M , et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12.
   PubMed Web of Science ®Google Scholar
• Hoff PM , Hochhaus A , Pestalozzi BC , Tebbutt NC , Li J , Kim TW , et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol. 2012;30(29):3596–603.
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF , Schulz J , McCleod M , Patel T , Hamm JT , Hecht JR , et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23(16):3697–705.
   PubMed Web of Science ®Google Scholar
• Cunningham D , Lang I , Marcuello E , Lorusso V , Ocvirk J , Shin DB , et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077–85.
   PubMed Web of Science ®Google Scholar
• Bennouna J , Sastre J , Arnold D , Osterlund P , Greil R , Van Cutsem E , et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37.
   PubMed Web of Science ®Google Scholar
• Maughan TS , Adams RA , Smith CG , Meade AM , Seymour MT , Wilson RH , et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103–14.
   PubMed Web of Science ®Google Scholar
• Douillard JY , Siena S , Cassidy J , Tabernero J , Burkes R , Barugel M , et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–705.
   PubMed Web of Science ®Google Scholar
• Kordatou Z , Kountourakis P , Papamichael D . Treatment of older patients with colorectal cancer: a perspective review. Ther Adv Med Oncol. 2014;6(3):128–40.
   PubMed Web of Science ®Google Scholar
• Kyriakou F , Kountourakis P , Papamichael D . Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients. Target Oncol. 2011;6(4):245–51.
   PubMed Web of Science ®Google Scholar